Tomohiro Akaba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomohiro Akaba has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Etsuko Tagaya
Department of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan
19 shared publicationsYuno Shiota
Department of Respiratory Medicine Tokyo Women's Medical University School of Medicine Shinjuku‐ku Tokyo Japan
10 shared publicationsMitsuko Kondo
Department of Respiratory Medicine, Tokyo Women's Medical University School of Medicine, 8-1 Kawada-cho, Shinjuku-ku, 162-8666, Tokyo, Japan
9 shared publicationsOsamitsu Yagi
9 shared publicationsKen Arimura
8 shared publications- Mitsuko Kondo
Department of Respiratory Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo, 162-8666, Japan
8 shared publications
Latest Publications
- Open Access
- 13 July 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70683
Good Syndrome Presenting With Pulmonary Abnormalities Four Years After Thymectomy
Good syndrome is a rare immunodeficiency associated with thymoma, characterized by hypogammaglobulinemia and marked B‐cell depletion. A 72‐year‐old woman who had undergone thymectomy 4 years earlier was referred to our hospital due to recurrent respiratory infections. Chest computed tomography revealed patchy ground‐glass opacities without evidence of thymoma recurrence. Bronchoalveolar lavage showed lymphocytosis, suggesting that the pulmonary abnormalities had possible inflammatory features, although infection could not be fully excluded. A short course of corticosteroids was added to empiric antibiotic therapy with careful monitoring, and the respiratory symptoms and radiological abnormalities improved after treatment. Because of her history of thymoma, further immunologic evaluation was performed and revealed profound hypogammaglobulinemia with near absence of peripheral B cells, leading to a diagnosis of Good syndrome. Intravenous immunoglobulin therapy was initiated, resulting in an increase in serum IgG levels and prevention of further respiratory infections. This case highlights that Good syndrome may become clinically apparent years after thymectomy and should be considered in patients with recurrent respiratory infections and unexplained pulmonary abnormalities.
- 13 July 2026
- Published by Wiley in Respirology Case Reports
- Vol. 14 (7) , e70683
Open AccessGood Syndrome Presenting With Pulmonary Abnormalities Four Years After Thymectomy
Good syndrome is a rare immunodeficiency associated with thymoma, characterized by hypogammaglobulinemia and marked B‐cell depletion. A 72‐year‐old woman who had undergone thymectomy 4 years earlier was referred to our hospital due to recurrent respiratory infections. Chest computed tomography revealed patchy ground‐glass opacities without evidence of thymoma recurrence. Bronchoalveolar lavage showed lymphocytosis, suggesting that the pulmonary abnormalities had possible inflammatory features, although infection could not be fully excluded. A short course of corticosteroids was added to empiric antibiotic therapy with careful monitoring, and the respiratory symptoms and radiological abnormalities improved after treatment. Because of her history of thymoma, further immunologic evaluation was performed and revealed profound hypogammaglobulinemia with near absence of peripheral B cells, leading to a diagnosis of Good syndrome. Intravenous immunoglobulin therapy was initiated, resulting in an increase in serum IgG levels and prevention of further respiratory infections. This case highlights that Good syndrome may become clinically apparent years after thymectomy and should be considered in patients with recurrent respiratory infections and unexplained pulmonary abnormalities.
- 5 July 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (7) , e70638
Regional Variation in Home Oxygen Therapy Use in Japan: An Age‐Standardized Ecological Analysis Using the NDB Open Data
Aim: To evaluate regional variation in home oxygen therapy (HOT) use in Japan and to examine its association with regional healthcare resources. Methods: This ecological cross‐sectional study analyzed aggregated data from the National Database Open Data for Fiscal Year 2023. Patients receiving HOT were identified using reimbursement codes. Age‐standardized claim ratios (SCRs) were calculated for all 47 prefectures by performing indirect standardization based on 5‐year age groups. Multivariable linear regression assessed associations between HOT use and prefecture‐level characteristics reflecting regional contextual factors, including the density of home‐care support clinics, respiratory specialist density, population aging, and respiratory disease‐related mortality. Results: A total of 324 998 patients had HOT‐related claims nationwide in Fiscal Year 2023. SCRs ranged from 54.4 to 140.4, indicating marked regional variation. A higher density of home‐care support clinics was independently associated with higher SCRs in both the primary model and the model additionally adjusted for population aging and regional disease burden. Population aging was inversely associated with SCRs, indicating lower age‐standardized HOT use in more aged prefectures. Respiratory disease‐related mortality was positively associated with SCRs, whereas no significant association was observed between respiratory specialist density and SCRs. Conclusions: Regional variation in HOT use was associated with the availability of home medical care services, after accounting for regional contextual factors. Lower age‐standardized use in highly aged prefectures may reflect regional characteristics related to HOT provision. These findings suggest an association between regional variation in HOT use and differences in home‐care infrastructure.
- 5 July 2026
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 26 (7) , e70638
Regional Variation in Home Oxygen Therapy Use in Japan: An Age‐Standardized Ecological Analysis Using the NDB Open Data
Aim: To evaluate regional variation in home oxygen therapy (HOT) use in Japan and to examine its association with regional healthcare resources. Methods: This ecological cross‐sectional study analyzed aggregated data from the National Database Open Data for Fiscal Year 2023. Patients receiving HOT were identified using reimbursement codes. Age‐standardized claim ratios (SCRs) were calculated for all 47 prefectures by performing indirect standardization based on 5‐year age groups. Multivariable linear regression assessed associations between HOT use and prefecture‐level characteristics reflecting regional contextual factors, including the density of home‐care support clinics, respiratory specialist density, population aging, and respiratory disease‐related mortality. Results: A total of 324 998 patients had HOT‐related claims nationwide in Fiscal Year 2023. SCRs ranged from 54.4 to 140.4, indicating marked regional variation. A higher density of home‐care support clinics was independently associated with higher SCRs in both the primary model and the model additionally adjusted for population aging and regional disease burden. Population aging was inversely associated with SCRs, indicating lower age‐standardized HOT use in more aged prefectures. Respiratory disease‐related mortality was positively associated with SCRs, whereas no significant association was observed between respiratory specialist density and SCRs. Conclusions: Regional variation in HOT use was associated with the availability of home medical care services, after accounting for regional contextual factors. Lower age‐standardized use in highly aged prefectures may reflect regional characteristics related to HOT provision. These findings suggest an association between regional variation in HOT use and differences in home‐care infrastructure.
- 14 May 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (4)
Impact of varenicline supply suspension on smoking cessation services in Japan's universal health insurance system
- 14 May 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (4)
Impact of varenicline supply suspension on smoking cessation services in Japan's universal health insurance system
- 12 May 2026
- Vol. 64 (4) , 101440
Impact of varenicline supply suspension on smoking cessation services in Japan's universal health insurance system.
We examined changes in smoking cessation service utilization and prescribing patterns under the universal health insurance system during the varenicline supply suspension in Japan. We analyzed publicly available aggregated data from the NDB Open Database, which covers more than 95% of all health insurance claims. Monthly claims for nicotine dependence management fees from April 2019 to March 2024 were evaluated using interrupted time-series analysis, and annual prescription trends for varenicline and nicotine patches were assessed. The varenicline supply suspension was associated with a significant immediate decline in service claims (-6443.5; 95% confidence interval: -8360.2 to -4526.9; p < 0.001). Claims showed a modest downward trend before the suspension, followed by a gradual increase thereafter. Varenicline use declined after 2021, accompanied by increased nicotine patch use. These findings indicate that the supply suspension disrupted smoking cessation services and altered prescribing patterns in Japan, highlighting vulnerability in systems with limited reimbursed therapies.
- 12 May 2026
- Vol. 64 (4) , 101440
Impact of varenicline supply suspension on smoking cessation services in Japan's universal health insurance system.
We examined changes in smoking cessation service utilization and prescribing patterns under the universal health insurance system during the varenicline supply suspension in Japan. We analyzed publicly available aggregated data from the NDB Open Database, which covers more than 95% of all health insurance claims. Monthly claims for nicotine dependence management fees from April 2019 to March 2024 were evaluated using interrupted time-series analysis, and annual prescription trends for varenicline and nicotine patches were assessed. The varenicline supply suspension was associated with a significant immediate decline in service claims (-6443.5; 95% confidence interval: -8360.2 to -4526.9; p < 0.001). Claims showed a modest downward trend before the suspension, followed by a gradual increase thereafter. Varenicline use declined after 2021, accompanied by increased nicotine patch use. These findings indicate that the supply suspension disrupted smoking cessation services and altered prescribing patterns in Japan, highlighting vulnerability in systems with limited reimbursed therapies.
- Open Access
- 1 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12) , e70424
Immunostaining and Ciliary Movement Analysis in Primary Ciliary Dyskinesia With a Homozygous Deletion Involving Exons 1–4 of DRC1 : A Case Report
Primary ciliary dyskinesia (PCD) presents various clinical manifestations, including bronchiectasis, chronic sinusitis, situs inversus, and infertility. PCD is diagnosed through multiple methods, including transmission electron microscopy (TEM), high‐speed video microscopy analysis (HSVA), immunofluorescence (IF), and genetic testing. Recent reports show that a homozygous deletion involving exons 1–4 of DRC1 is common in Japanese patients with PCD. We report the case of a 29‐year‐old male without situs inversus previously diagnosed with diffuse panbronchiolitis, who underwent PCD testing. TEM appeared almost normal, and HSVA showed motile cilia with reduced amplitude. Genetic testing revealed a homozygous deletion involving exons 1–4 of DRC1 . Due to lack of a suitable DRC1 antibody for IF, we used the DRC3 antibody as in previous studies. IF showed the absence of DRC3 in the cilia, suggesting a DRC1 deletion affects DRC3 localization in the cilia. To the best of our knowledge, this case represents one of the earliest reports to perform IF and ciliary movement analysis in PCD with a homozygous deletion involving exons 1–4 of DRC1 .
- 1 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12) , e70424
Open AccessImmunostaining and Ciliary Movement Analysis in Primary Ciliary Dyskinesia With a Homozygous Deletion Involving Exons 1–4 of DRC1 : A Case Report
Primary ciliary dyskinesia (PCD) presents various clinical manifestations, including bronchiectasis, chronic sinusitis, situs inversus, and infertility. PCD is diagnosed through multiple methods, including transmission electron microscopy (TEM), high‐speed video microscopy analysis (HSVA), immunofluorescence (IF), and genetic testing. Recent reports show that a homozygous deletion involving exons 1–4 of DRC1 is common in Japanese patients with PCD. We report the case of a 29‐year‐old male without situs inversus previously diagnosed with diffuse panbronchiolitis, who underwent PCD testing. TEM appeared almost normal, and HSVA showed motile cilia with reduced amplitude. Genetic testing revealed a homozygous deletion involving exons 1–4 of DRC1 . Due to lack of a suitable DRC1 antibody for IF, we used the DRC3 antibody as in previous studies. IF showed the absence of DRC3 in the cilia, suggesting a DRC1 deletion affects DRC3 localization in the cilia. To the best of our knowledge, this case represents one of the earliest reports to perform IF and ciliary movement analysis in PCD with a homozygous deletion involving exons 1–4 of DRC1 .
- Open Access
- 20 November 2025
- Published by Elsevier in World Allergy Organization Journal
- Vol. 18 (11) , 101139
Clinical characteristics and outcomes of acute eosinophilic pneumonia: A nationwide descriptive study
- 20 November 2025
- Published by Elsevier in World Allergy Organization Journal
- Vol. 18 (11) , 101139
Open AccessClinical characteristics and outcomes of acute eosinophilic pneumonia: A nationwide descriptive study
- 24 September 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1174-1178
Geographic variation in bronchoscopy use across Japan: A nationwide analysis using administrative claims data
- 24 September 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1174-1178
Geographic variation in bronchoscopy use across Japan: A nationwide analysis using administrative claims data
- 30 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1066-1069
Nationwide trends in the use of antitussive agents in Japan before, during, and after the COVID-19 Pandemic: A descriptive study using a National Database
- 30 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1066-1069
Nationwide trends in the use of antitussive agents in Japan before, during, and after the COVID-19 Pandemic: A descriptive study using a National Database
- 26 July 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 915-917
Nationwide trends in utilization and expenditure of biologic agents approved for asthma in Japan: Insights from the national database (2014–2023)
- 26 July 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 915-917
Nationwide trends in utilization and expenditure of biologic agents approved for asthma in Japan: Insights from the national database (2014–2023)